Klein, Anders B.
Nicolaisen, Trine S. http://orcid.org/0000-0001-5856-6443
Ørtenblad, Niels http://orcid.org/0000-0001-9060-4139
Gejl, Kasper D.
Jensen, Rasmus http://orcid.org/0000-0003-0112-6185
Fritzen, Andreas M. http://orcid.org/0000-0001-8793-9739
Larsen, Emil L. http://orcid.org/0000-0002-0676-0858
Karstoft, Kristian
Poulsen, Henrik E.
Morville, Thomas
Sahl, Ronni E. http://orcid.org/0000-0002-7276-2384
Helge, Jørn W. http://orcid.org/0000-0001-9724-5423
Lund, Jens http://orcid.org/0000-0003-2338-6033
Falk, Sarah
Lyngbæk, Mark
Ellingsgaard, Helga http://orcid.org/0000-0002-9105-5247
Pedersen, Bente K. http://orcid.org/0000-0001-6508-6288
Lu, Wei
Finan, Brian http://orcid.org/0000-0002-6467-0447
Jørgensen, Sebastian B. http://orcid.org/0000-0002-9648-0971
Seeley, Randy J. http://orcid.org/0000-0002-3721-5625
Kleinert, Maximilian
Kiens, Bente http://orcid.org/0000-0001-5705-5625
Richter, Erik A. http://orcid.org/0000-0002-6850-3056
Clemmensen, Christoffer http://orcid.org/0000-0003-2456-9667
Funding for this research was provided by:
Lundbeckfonden (R238-2016-2859)
Novo Nordisk Fonden (NNF17OC0026114, NNF18CC0034900)
Det Frie Forskningsråd (0134-00254B)
Article History
Received: 12 May 2020
Accepted: 22 January 2021
First Online: 15 February 2021
Competing interests
: S.B.J., W.L., and B.F. are working for Novo Nordisk A/S, a pharmaceutical company producing and selling medicine for the treatment of chronic diseases including diabetes and obesity. E.L.L. and H.E.P. have received an unrestricted research grant from Boehringer Ingelheim for an unrelated investigator-initiated study. R.J.S. has received research support from Zafgen, Novo Nordisk, Ionis, AstraZeneca, and Pfizer. R.J.S. has served on scientific advisory boards for Novo Nordisk, Sanofi, Scohia, Ionis, Kintai Therapeutics, and GuidePoint Consultants. R.J.S. is a stakeholder of Zafgen and Redesign Health. The other authors have declared that no competing interests exist.